|
|
|
| Application of molecular probes in nuclear imaging of neuroendocrine tumors |
YAN Jing( ),ZHANG Tingting,ZHAO Kui() |
| Department of PET，the First Affiliated Hospital，Zhejiang University School of Medicine，Hangzhou 310003，China |
|
|
|
Abstract Neuroendocrine tumors are a type of heterogeneous tumors originating from neuroendocrine cells derived from the neural crest，which can secrete a variety of amines and peptide hormones.Based on different molecular biomarkers，histologic types and differentiation degrees，individualized nuclear imaging can provide information for the early diagnosis，clinical staging，treatment guidance，and detection of the recurrence and metastasis of neuroendocrine tumor. In this paper，we review the development and application of nuclear medicine molecular imaging probes such as glucose analogs，somatostatin analogues，amine precursors，hormone analogs and enzyme inhibitors in the diagnosis and treatment of neuroendocrine tumors.
|
|
Received: 03 August 2020
Published: 16 May 2021
|
|
|
|
Corresponding Authors:
ZHAO Kui
E-mail: yanjing9986@163.com;zyzhaokui@163.com
|
核医学分子影像探针应用于神经内分泌肿瘤的研究进展
神经内分泌肿瘤起源于神经嵴来源的神经内分泌细胞，可分泌多种胺和多肽激素进入全身循环。核医学分子影像探针在神经内分泌肿瘤的早期诊断、临床分期、治疗方案选择、复发和转移病灶的探查中具有重要意义，临床可根据神经内分泌肿瘤细胞增殖及分化程度、细胞表面的分子表达、肿瘤部位选择分子影像探针进行个体化显像。本文就葡萄糖类似物显像剂、生长抑素类似物显像剂、胺前体类显像剂、激素类似物显像剂和酶抑制剂类显像剂等核医学分子影像探针在神经内分泌肿瘤诊断和治疗中的发展及应用进行综述。
关键词：
神经内分泌肿瘤,
诊断,
分子探针,
核医学显像,
综述
|
|
| [1] |
YAO J C, HASSAN M, PHAN A, et al. One hundred years after “carcinoid”:epidemiology of and prognostic factors for neuroendocrine tumors in 35，825 cases in the United States [J]. J Clin Oncol, 2008, 26(18): 3063-3072.
doi: 10.1200/JCO.2007.15.4377
|
|
|
| [2] |
DASARI A, SHEN C, HALPERIN D, et al. Trends in the incidence，prevalence，and survival outcomes in patients with neuroendocrine tumors in the United States [J]. JAMA Oncol, 2017, 3(10): 1335.
doi: 10.1001/jamaoncol.2017.0589
|
|
|
| [3] |
KIM J Y, HONG S M, RO J Y . Recent updates on grading and classification of neuroendocrine tumors [J]. Ann Diagnostic Pathol, 2017, 11-16.
doi: 10.1016/j.anndiagpath.2017.04.005
|
|
|
| [4] |
王 玲，胡桂兰，乔 真，等. 神经内分泌肿瘤转移灶PET/CT生长抑素受体显像特点分析[J]. 中华核医学与分子影像杂志，2017，37（3）: 132136. DOI: 10.3760/cma.j.issn.2095-2848.2017.03.003 .
|
|
|
| [5] |
PRASAD V, AMBROSINI V, HOMMANN M, et al. Detection of unknown primary neuroendocrine tumours （CUP-NET） using 68Ga-DOTA-NOC receptor PET/CT [J]. Eur J Nucl Med Mol Imag, 2010, 37(1): 67-77.
doi: 10.1007/s00259-009-1205-y
|
|
|
| [6] |
姚晓晨，王 峰. 胃肠胰神经内分泌肿瘤的影像学诊断[J]. 浙江大学学报（医学版），2016，45（1）: 51–55. DOI: 10.3785/j.issn.1008-9292.2016.01.08 .
|
|
|
| [7] |
HAS SIMSEK D, KUYUMCU S, TURKMEN C, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastro- enteropancreatic neuroendocrine tumors? [J]. J Nucl Med, 2014, 55(11): 1811-1817.
doi: 10.2967/jnumed.114.142224
|
|
|
| [8] |
BUCAU M, LAURENT-BELLUE A, POTé N, et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation [J]. Neuroendocrinology, 2018, 106(3): 274-282.
doi: 10.1159/000480239
|
|
|
| [9] |
VAN ESSEN M, SUNDIN A, KRENNING E P, et al. Neuroendocrine tumours:the role of imaging for diagnosis and therapy [J]. Nat Rev Endocrinol, 2014, 10(2): 102-114.
doi: 10.1038/nrendo.2013.246
|
|
|
| [10] |
ZER A, DOMACHEVSKY L, RAPSON Y, et al. The role of 18F-FDG PET/CT on staging and prognosis in patients with small cell lung cancer [J]. Eur Radiol, 2016, 26(9): 3155-3161.
doi: 10.1007/s00330-015-4132-2
|
|
|
| [11] |
KAUHANEN S, SCHALIN-J?NTTI C, SEPP?NEN M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer [J]. J Nucl Med, 2011, 52(12): 1855-1863.
doi: 10.2967/jnumed.111.094771
|
|
|
| [12] |
GEIJER H, BREIMER L H . Somatostatin receptor PET/CT in neuroendocrine tumours:update on systematic review and meta-analysis [J]. Eur J Nucl Med Mol Imag, 2013, 40(11): 1770-1780.
doi: 10.1007/s00259-013-2482-z
|
|
|
| [13] |
KAEMMERER D, PETER L, LUPP A, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours [J]. Eur J Nucl Med Mol Imag, 2011, 38(9): 1659-1668.
doi: 10.1007/s00259-011-1846-5
|
|
|
| [14] |
LOCOCO F, PEROTTI G, CARDILLO G, et al. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid [J/OL]. Clin Nucl Med, 2015, 40(3): e183-e189.
doi: 10.1097/RLU.0000000000000641
|
|
|
| [15] |
NASWA N, SHARMA P, SUMAN KC S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma [J]. Nucl Med Commun, 2012, 33(7): 766-774.
doi: 10.1097/MNM.0b013e3283541157
|
|
|
| [16] |
HERRMANN K, CZERNIN J, WOLIN E M, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors:the referring physician’s perspective [J]. J Nucl Med, 2015, 56(1): 70-75.
doi: 10.2967/jnumed.114.148247
|
|
|
| [17] |
LONG T, YANG N, ZHOU M, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms [J]. Clin Nucl Med, 2019, 44(6): 452-458.
doi: 10.1097/RLU.0000000000002578
|
|
|
| [18] |
刘会攀，陈 跃. 放射性核素诊治神经内分泌肿瘤的应用进展[J]. 中华核医学与分子影像杂志，2019，39（9）: 564567.DOI: 10.3760/cma.j.issn.2095-2848.2019.09.015 .
|
|
|
| [19] |
GRISANTI S, FILICE A, BASILE V, et al. Treatment with 90Y/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors [J/OL]. J Clin Endocrinol Metab, 2020, 105(3): e1-e5.
doi: 10.1210/clinem/dgz091
|
|
|
| [20] |
RUFINI V, BAUM R P, CASTALDI P, et al. Role of PET/CT in the functional imaging of endocrine pancreatic tumors [J]. Abdom Imag, 2012, 37(6): 1004-1020.
doi: 10.1007/s00261-012-9871-9
|
|
|
| [21] |
SANTHANAM P, CHANDRAMAHANTI S, KROISS A, et al. Nuclear imaging of neuroendocrine tumors with unknown primary:why，when and how? [J]. Eur J Nucl Med Mol Imag, 2015, 42(7): 1144-1155.
doi: 10.1007/s00259-015-3027-4
|
|
|
| [22] |
NANNI C, RUBELLO D, FANTI S . 18F-DOPA PET/CT and neuroendocrine tumours[J]. Eur J Nucl Med Mol Imag, 2006, 33(5): 509-513.
doi: 10.1007/s00259-006-0079-5
|
|
|
| [23] |
BANDOPADHYAYA G P，KUMAR A，KUMARI J. Role of （18）F-DOPA PET/CT and （131）I-MIBG planar scintigraphy in evaluating patients with pheochromocytoma[J]. Hell J Nucl Med，2015，18 Suppl 1:141 .
|
|
|
| [24] |
BACCA A, CHIACCHIO S, ZAMPA V, et al. Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas [J]. Clin Nucl Med, 2014, 39(1): 14-20.
doi: 10.1097/RLU.0000000000000242
|
|
|
| [25] |
BOZKURT M F, VIRGOLINI I, BALOGOVA S, et al. Erratum to:Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA [J]. Eur J Nucl Med Mol Imag, 2017, 44(12): 2150-2151.
doi: 10.1007/s00259-017-3807-0
|
|
|
| [26] |
IMPERIALE A, RUST E, GABRIEL S, et al. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin:relation to tumor origin and differentiation[J]. J Nucl Med, 2014, 55(3): 367-372.
doi: 10.2967/jnumed.113.126896
|
|
|
| [27] |
KUIK W J, KEMA I P, BROUWERS A H, et al. In vivo biodistribution of no-carrier-added 6-18F-fluoro-3，4-dihydroxy-L-phenylalanine （18F-DOPA），produced by a new nucleophilic substitution approach，compared with carrier-added 18F-DOPA，prepared by conventional electrophilic substitution [J] . J Nucl Med, 2015, 56(1): 106-112.
doi: 10.2967/jnumed.114.145730
|
|
|
| [28] |
ORLEFORS H, SUNDIN A, LU L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography [J]. Eur J Nucl Med Mol Imag, 2006, 33(1): 60-65.
doi: 10.1007/s00259-005-1891-z
|
|
|
| [29] |
PASHANKAR F D，O′DORISIO M S，MENDA Y. MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use[J]. J Nucl Med，2005，46 Suppl 1:55S–61S .
|
|
|
| [30] |
YAMAMOTO S, HELLMAN P, WASSBERG C, et al. 11C-hydroxyephedrine positron emission tomography imaging of pheochromocytoma:a single center experience over 11 years [J]. J Clin Endocrinol Metab, 2012, 97(7): 2423-2432.
doi: 10.1210/jc.2011-3342
|
|
|
| [31] |
HAHNER S, SUNDIN A . Metomidate-based imaging of adrenal masses [J]. HORM CANC, 2011, 2(6): 348-353.
doi: 10.1007/s12672-011-0093-3
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
